NLRP3 and type 2 diabetes mellitus: CY-09 directly targets NLRP3, inhibiting its inflammasome activation in vivo, and has shown significant therapeutic effects in mouse models of NLRP3-driven diseases, such as type 2 diabetes and CAPS (128).